Granulocyte colony-stimulating factor

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma

Retrieved on: 
Monday, April 17, 2023

TEL AVIV, Israel, April 17, 2023 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced the publication of data from the Company's GENESIS Phase 3 clinical trial in the peer-reviewed journal Nature Medicine.  The international GENESIS trial evaluated the safety and efficacy of the Company's lead investigational candidate motixafortide plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF for the mobilization of hematopoietic stem cells in patients with multiple myeloma prior to autologous stem cell transplantation (ASCT).

Key Points: 
  • The international GENESIS trial evaluated the safety and efficacy of the Company's lead investigational candidate motixafortide plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF for the mobilization of hematopoietic stem cells in patients with multiple myeloma prior to autologous stem cell transplantation (ASCT).
  • The clinical trial found that all primary and secondary endpoints were achieved with a statistical significance of p
  • These data highlight the potential of motixafortide plus G-CSF, if approved, to enhance the treatment options for clinicians and patients with multiple myeloma undergoing ASCT."
  • "We look forward to continuing the development of motixafortide with the aim of advancing care for patients with multiple myeloma."

Oncology Biosimilars Global Market Report 2022: Robust Pipeline of Monoclonal Antibodies to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022

The "Oncology Biosimilars Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncology Biosimilars Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, organized regulatory bodies to monitor oncology biosimilar approvals are further driving the market in Europe.
  • Currently, approximately 30 percent of all the biosimilars in the pipeline that await FDA approval are monoclonal antibodies.
  • In 2021, Europe occupied largest share of the global market share for oncology biosimilars.

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

Retrieved on: 
Thursday, December 1, 2022

The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer inthe United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights

Retrieved on: 
Thursday, November 3, 2022

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today reported financial results for the third quarter ending September 30, 2022, and recent program highlights.

Key Points: 
  • We are building momentum in the MGTA-117 clinical trial with new clinical results and are making progress across our pipeline, including our second targeted conditioning program CD45-ADC, said Jason Gardner, President and Chief Executive Officer of Magenta Therapeutics, Inc.
  • The program is currently enrolling patients with relapsed/refractory acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), in a Phase 1/2 dose escalation clinical trial.
  • In addition, Magenta has enrolled a sufficient number of patients to complete Cohort 3, provided that the patients complete their respective dose-limiting toxicity (DLT) observation periods.
  • Magenta has initiated requests for formal engagement with multiple regulatory authorities for the purpose of transitioning the clinical program into transplant-eligible AML and MDS patients.

Biosimilars Global Market Opportunities and Strategies Report 2022: Long-term Forecast to 2026 & 2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 5, 2022

The "Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.
  • The market is then expected to grow at a CAGR of 18.0% from 2026 and reach $59,555.8 million in 2031.
  • This report describes and explains the biosimilars market and covers 2016-2021, termed the historic period, and 2021-2026 termed the forecast period, along with further forecasts for the period 2026-2031.
  • The global biosimilars market is concentrated, with a small number of large players in the market.

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022

The "G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022: By Type, By Application, By Product" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022: By Type, By Application, By Product" report has been added to ResearchAndMarkets.com's offering.
  • The G-CSF (Granolocyte Colony Stimulating Factors) market global report answers all these questions and many more.
  • Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco)
    6.2.
  • Global G-CSF (Granulocyte Colony Stimulating Factors) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Thursday, May 26, 2022

The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).
  • We look forward to continuing to advance this trial and exploring TARA-002s full potential in NMIBC.
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer inthe United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.

BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, April 28, 2022

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, today announced three poster presentations relating to lead asset plinabulin at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022, in Chicago, Illinois and virtually.

Key Points: 
  • NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs, today announced three poster presentations relating to lead asset plinabulin at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022, in Chicago, Illinois and virtually.
  • The other two posters contain new data from the DUBLIN-3 Phase 3 non-small cell lung cancer (NSCLC) treatment program.
  • One focuses on a quality of life (QoL) analysis that compares patients who received plinabulin with docetaxel versus those who didnt.
  • The other includes the results of a subgroup analysis in non-squamous NSCLC patients.

Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Thursday, March 24, 2022

In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.

Key Points: 
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.
  • NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Global Oncology Biosimilars Market (2022 to 2031) - Featuring Pfizer, Amgen and Hospira Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022

The main drug types of oncology biosimilars are monoclonal antibody, immunomodulators, hematopoietic agents and granulocyte colony-stimulating factor (G-CSF).

Key Points: 
  • The main drug types of oncology biosimilars are monoclonal antibody, immunomodulators, hematopoietic agents and granulocyte colony-stimulating factor (G-CSF).
  • The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.
  • The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market.
  • Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.